Genetic Testing For Tamoxifen, Warfarin, Plavix Lacks “Clear Value,” Express Scripts Says
Executive Summary
Express Scripts’ caution about the cost effectiveness of some genetic testing could hint at how interested it will be in continuing the pharmacogenomic programs sponsored by former rival PBM Medco, which Express acquired in early April.
You may also be interested in...
Express Scripts Realignment Identifies Non-Core Businesses
Express Scripts is “looking at strategic alternatives” for some of its non-core businesses, which include international ventures, UBC and PolyMedica.
Express Scripts-Medco Merger Closes With No Divestitures Needed
The FTC voted in a split 3-1 vote to close its investigation and allow Express Scripts’ $29.1 billion acquisition of rival PBM Medco to proceed.
Medco, AssureRx Partner In Trial To Improve Psychotropic Medication Adherence Through Genetic Testing
Medco does not expect results to alter reimbursement decisions, but to offer another tool to help physicians make prescribing decisions.